Arcus Biosciences, Inc. Common Stock (RCUS)
14.48
+1.13 (8.46%)
NYSE · Last Trade: Oct 6th, 11:25 PM EDT
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached.
Via Benzinga · October 6, 2025
Via Benzinga · September 3, 2025
On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play.
Via Benzinga · August 14, 2025
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.
Via Benzinga · August 8, 2025

Via Benzinga · November 6, 2024
Via Benzinga · May 6, 2025
Via Benzinga · May 6, 2025
Via Benzinga · April 23, 2025

Via Benzinga · October 3, 2024

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering.
Via Benzinga · February 18, 2025

Via Benzinga · January 31, 2025

Via Benzinga · January 24, 2025

Via Benzinga · January 24, 2025

Via Benzinga · October 8, 2024

Via Benzinga · August 9, 2024

Via Benzinga · July 8, 2024

RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response rates. New data from the ARC-9 study highlights significant survival benefits in metastatic colorectal cancer.
Via Benzinga · June 3, 2024